{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IDS&page=2",
    "query": {
      "intervention": "IDS",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IDS&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-12T17:11:24.291Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07815704",
      "title": "Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancers",
        "Primary Peritoneal Cancer",
        "High Grade Serous Adenocarcinoma of Ovary"
      ],
      "interventions": [
        {
          "name": "Standard of Care + atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care (SOC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 89 Years · Female only"
      },
      "enrollment_count": 40,
      "start_date": "2026-09",
      "completion_date": "2031-08",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-09-12T17:11:24.291Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07815704"
    },
    {
      "nct_id": "NCT04628871",
      "title": "Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemophilia B",
        "Mucopolysaccharidosis I",
        "Mucopolysaccharidosis II"
      ],
      "interventions": [
        {
          "name": "SB-318",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SB-913",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SB-FIX",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sangamo Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2020-11-03",
      "completion_date": "2026-06-17",
      "has_results": false,
      "last_update_posted_date": "2026-08-13",
      "last_synced_at": "2026-09-12T17:11:24.291Z",
      "location_count": 5,
      "location_summary": "Oakland, California • Chicago, Illinois • New York, New York + 2 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04628871"
    },
    {
      "nct_id": "NCT04638127",
      "title": "PREEMIE PROGRESS: A Family Management Program for Parents of Preterm Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Premature Infant Disease",
        "Family Research",
        "Parent-Child Relations",
        "Self Efficacy",
        "Patient Engagement",
        "Patient Empowerment",
        "Parenting",
        "Chronic Conditions, Multiple"
      ],
      "interventions": [
        {
          "name": "PREEMIE PROGRESS",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Attention Control",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2022-05-17",
      "completion_date": "2023-12-31",
      "has_results": true,
      "last_update_posted_date": "2025-06-27",
      "last_synced_at": "2026-09-12T17:11:24.291Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04638127"
    },
    {
      "nct_id": "NCT00937794",
      "title": "Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase®",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hunter Syndrome"
      ],
      "interventions": [
        {
          "name": "Neurobehavioral testing",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Visual and auditory assessments",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "32 Months",
        "maximum_age": "18 Years",
        "sex": "MALE",
        "summary": "32 Months to 18 Years · Male only"
      },
      "enrollment_count": 33,
      "start_date": "2009-07-02",
      "completion_date": "2011-07-13",
      "has_results": true,
      "last_update_posted_date": "2021-06-14",
      "last_synced_at": "2026-09-12T17:11:24.291Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00937794"
    },
    {
      "nct_id": "NCT01506141",
      "title": "An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hunter Syndrome"
      ],
      "interventions": [
        {
          "name": "Idursulfase-IT",
          "type": "DRUG"
        },
        {
          "name": "Elaprase",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "18 Years",
        "sex": "MALE",
        "summary": "3 Years to 18 Years · Male only"
      },
      "enrollment_count": 15,
      "start_date": "2010-08-01",
      "completion_date": "2024-04-30",
      "has_results": true,
      "last_update_posted_date": "2025-08-06",
      "last_synced_at": "2026-09-12T17:11:24.291Z",
      "location_count": 7,
      "location_summary": "Chicago, Illinois • Chapel Hill, North Carolina • Portland, Oregon + 4 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01506141"
    },
    {
      "nct_id": "NCT07236606",
      "title": "RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "MPS II",
        "Hunter Syndrome (MPS II)"
      ],
      "interventions": [
        {
          "name": "RGX-121-3102",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "REGENXBIO Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Months",
        "maximum_age": "5 Years",
        "sex": "MALE",
        "summary": "4 Months to 5 Years · Male only"
      },
      "enrollment_count": 2,
      "start_date": "2025-11-25",
      "completion_date": "2031-05-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-09-12T17:11:24.291Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07236606"
    },
    {
      "nct_id": "NCT01342757",
      "title": "Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Adult Glioblastoma",
        "Depression",
        "Recurrent Adult Brain Tumor"
      ],
      "interventions": [
        {
          "name": "vorinostat",
          "type": "DRUG"
        },
        {
          "name": "temozolomide",
          "type": "DRUG"
        },
        {
          "name": "magnetic resonance spectroscopic imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "survey administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2010-12",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2018-01-29",
      "last_synced_at": "2026-09-12T17:11:24.291Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01342757"
    },
    {
      "nct_id": "NCT04573023",
      "title": "A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Mucopolysaccharidosis II"
      ],
      "interventions": [
        {
          "name": "JR-141",
          "type": "DRUG"
        },
        {
          "name": "Idursulfase",
          "type": "DRUG"
        },
        {
          "name": "JR-141 or Idursulfase",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "JCR Pharmaceuticals Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 86,
      "start_date": "2022-02-14",
      "completion_date": "2027-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-09-12T17:11:24.291Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • Oakland, California • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04573023"
    },
    {
      "nct_id": "NCT05238324",
      "title": "Safety and Efficacy of HMI-203 in ERT-Treated Adults With MPS II",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Mucopolysaccharidosis II"
      ],
      "interventions": [
        {
          "name": "Genetic HMI-203",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Homology Medicines, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "18 Years to 45 Years · Male only"
      },
      "enrollment_count": 0,
      "start_date": "2022-09-08",
      "completion_date": "2029-01",
      "has_results": false,
      "last_update_posted_date": "2023-08-28",
      "last_synced_at": "2026-09-12T17:11:24.291Z",
      "location_count": 5,
      "location_summary": "Oakland, California • New Haven, Connecticut • Hackensack, New Jersey + 2 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05238324"
    },
    {
      "nct_id": "NCT04410289",
      "title": "Defining the 'Sniffing Position\" in Infants and Toddlers - A Pilot Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Airway Management",
        "Infant ALL",
        "Children, Only",
        "Endotracheal Intubation"
      ],
      "interventions": [
        {
          "name": "Airway positioning per specified protocol followed by Direct Laryngoscopy and Endotracheal Intubation",
          "type": "PROCEDURE"
        },
        {
          "name": "Airway positioning per provider preference followed by Direct Laryngoscopy and Endotracheal Intubation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Tufts Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "48 Months",
        "sex": "ALL",
        "summary": "1 Month to 48 Months"
      },
      "enrollment_count": 40,
      "start_date": "2019-07-01",
      "completion_date": "2019-12-26",
      "has_results": false,
      "last_update_posted_date": "2020-06-04",
      "last_synced_at": "2026-09-12T17:11:24.291Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04410289"
    }
  ]
}